AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$RLAY

Bergstrom Donald A sold $162K of RLAY

Bergstrom Donald A (President, R&D) sold 8,530 shares of Relay Therapeutics, Inc. (RLAY) at $18.97 ($0.16M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bergstrom Donald A
Published Sep 9, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLAY
Neutral
medium confidence
Mentioned
$RLAY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited actionable insight for traders.

02

Market read

Primary relevance is to shareholders monitoring insider activity; unlikely to move the stock.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this small sale.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑08

Background

Form 4 filings disclose insider transactions; a sale under a 10b5‑1 plan is routine.

Company-level read

Ticker impact

$RLAYNeutralMedium confidence
Context

President of R&D sold 8,530 shares for $161,814 via a 10b5‑1 plan.

Expected impact

Minimal short‑term price pressure; likely no material move.

Evidence & confidence

The sale represents ~0.2% of insider holdings and is pre‑arranged, reducing informational value.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to Relay Therapeutics shareholders.

Counterpoint

What could challenge this read

Insider may be diversifying; could be a neutral or positive signal if cash is redeployed.

Key entities

  • Company
    Relay Therapeutics, Inc.

    Biopharma developing precision medicines.

  • Insider
    Donald A. Bergstrom

    President, R&D at Relay Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

AUG 6
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K6 min
JUN 2
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com1 min